Alcohol Dependence Disrupted the Brain's Natural Cannabinoid System in the Amygdala
Alcohol-dependent rats showed decreased 2-AG endocannabinoid levels in the central amygdala, which was linked to anxiety-like behavior and excessive drinking - effects reversed by boosting 2-AG with MAGL inhibitors.
Quick Facts
What This Study Found
Alcohol dependence decreased baseline 2-AG levels and increased glutamate and GABA in the central amygdala. Acute withdrawal intensified these changes. Re-exposure to alcohol restored 2-AG and GABA levels. MAGL inhibitors (which boost 2-AG) reduced both anxiety-like behavior and excessive alcohol consumption in dependent animals.
Key Numbers
Alcohol dependence decreased baseline 2-AG and increased glutamate and GABA. MAGL inhibitors MJN110 (10 and 20 mg/kg in rats) and JZL184 (1 and 3 mg/kg in mice) reduced anxiety and excessive drinking.
How They Did This
Rats and mice were made alcohol-dependent through chronic intermittent exposure. In vivo microdialysis measured endocannabinoid and amino acid levels in the central amygdala. Pharmacological studies tested the effects of endocannabinoid-boosting drugs on anxiety and alcohol consumption.
Why This Research Matters
This study reveals that the endocannabinoid system in the amygdala - a key brain region for emotional processing - becomes dysregulated in alcohol dependence. This provides a biological mechanism for why alcohol-dependent individuals experience anxiety during withdrawal and drink excessively.
The Bigger Picture
The endocannabinoid system may be a common thread linking different substance use disorders. This study shows that alcohol dependence fundamentally alters endocannabinoid signaling in ways that promote continued use, suggesting that endocannabinoid-based therapies could treat multiple addictions.
What This Study Doesn't Tell Us
Animal study results may not translate directly to humans. The specific doses and administration routes are experimental. The central amygdala is one of many brain regions involved in addiction.
Questions This Raises
- ?Could MAGL inhibitors treat alcohol use disorder in humans?
- ?Does cannabis use affect alcohol dependence through this same endocannabinoid mechanism?
- ?Are similar 2-AG deficits found in human alcoholics?
Trust & Context
- Key Stat:
- MAGL inhibitors that boosted 2-AG levels reduced both anxiety-like behavior and excessive alcohol consumption in dependent animals.
- Evidence Grade:
- Moderate - multi-method approach combining microdialysis, pharmacology, and behavioral testing across two species, but all preclinical.
- Study Age:
- Published in 2018.
- Original Title:
- Deficient endocannabinoid signaling in the central amygdala contributes to alcohol dependence-related anxiety-like behavior and excessive alcohol intake.
- Published In:
- Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 43(9), 1840-1850 (2018)
- Authors:
- Serrano, Antonia(6), Pavon, Francisco J(2), Buczynski, Matthew W(2), Schlosburg, Joel, Natividad, Luis A, Polis, Ilham Y, Stouffer, David G, Zorrilla, Eric P, Roberto, Marisa, Cravatt, Benjamin F, Martin-Fardon, Rémi, Rodriguez de Fonseca, Fernando, Parsons, Loren H
- Database ID:
- RTHC-01833
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
How does the endocannabinoid system relate to alcohol addiction?
This study found that alcohol dependence depleted the endocannabinoid 2-AG in the central amygdala, a brain region critical for emotional processing. This depletion was linked to anxiety and excessive drinking, and restoring 2-AG levels reversed both effects.
Could targeting the endocannabinoid system treat alcoholism?
This animal study suggests yes. Drugs that boosted the endocannabinoid 2-AG (MAGL inhibitors) reduced both withdrawal anxiety and excessive alcohol consumption in dependent animals, pointing to a potential therapeutic approach.
Read More on RethinkTHC
- cannabis-dependence-physical-psychological-addiction-science
- cannabis-perception-vs-evidence-gap
- cannabis-use-disorder-test
- cross-addiction-quit-weed-start-drinking
- is-weed-addictive
- is-weed-addictive-science
- quitting-weed-and-alcohol
- rehab-for-weed-addiction-necessary
- signs-of-cannabis-use-disorder
- weed-vape-pen-addiction
Cite This Study
https://rethinkthc.com/research/RTHC-01833APA
Serrano, Antonia; Pavon, Francisco J; Buczynski, Matthew W; Schlosburg, Joel; Natividad, Luis A; Polis, Ilham Y; Stouffer, David G; Zorrilla, Eric P; Roberto, Marisa; Cravatt, Benjamin F; Martin-Fardon, Rémi; Rodriguez de Fonseca, Fernando; Parsons, Loren H. (2018). Deficient endocannabinoid signaling in the central amygdala contributes to alcohol dependence-related anxiety-like behavior and excessive alcohol intake.. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 43(9), 1840-1850. https://doi.org/10.1038/s41386-018-0055-3
MLA
Serrano, Antonia, et al. "Deficient endocannabinoid signaling in the central amygdala contributes to alcohol dependence-related anxiety-like behavior and excessive alcohol intake.." Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2018. https://doi.org/10.1038/s41386-018-0055-3
RethinkTHC
RethinkTHC Research Database. "Deficient endocannabinoid signaling in the central amygdala ..." RTHC-01833. Retrieved from https://rethinkthc.com/research/serrano-2018-deficient-endocannabinoid-signaling-in
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.